APA (7th ed.) Citation

Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., . . . Konstan, M. W. (2012). Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax, 67(1), 12-18. https://doi.org/10.1136/thoraxjnl-2011-200393

Chicago Style (17th ed.) Citation

Clancy, J P., et al. "Results of a Phase IIa Study of VX-809, an Investigational CFTR Corrector Compound, in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation." Thorax 67, no. 1 (2012): 12-18. https://doi.org/10.1136/thoraxjnl-2011-200393.

MLA (9th ed.) Citation

Clancy, J P., et al. "Results of a Phase IIa Study of VX-809, an Investigational CFTR Corrector Compound, in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation." Thorax, vol. 67, no. 1, 2012, pp. 12-18, https://doi.org/10.1136/thoraxjnl-2011-200393.